1. Recurrent VTE occurred in 2.1% in the reduced-dose group and 2.8% in the full-dose group, with HR 0.76 (was...

1 .The objective response rate was 88.8% for TKI-naïve patients and 55.8% for TKI-pretreated patients. 2. Most common adverse events...

1. A total of 2% of the eligible population was diagnosed with lung cancer after a positive screen on baseline...

1. Overall survival at 2 years was 74% for active surveillance and 71% for standard surgery. 2. Median disease-free survival...

1. Cooling was found to have a relative risk reduction of 42% and compression had a relative risk reduction of...

1. Intracranial objective response rate was 51% with ipilimumab plus nivolumab and 20% with nivolumab alone. 2. Treatment-related grade 3...

1. Overall objective response rate was 30%, with 1 patient having a complete response. 2. Grade 3-4 treatment-related events occurred...

1. Invasive disease-free survival occurred in 19.7% of the T-DM1 group and 32.2% in the trastuzumab group, with an HR...

1. Median event-free survival was 54.8 months with immunotherapy vs 20.9 months with chemotherapy, with HR 0.77 (non-significant). 2. Grade...

1. Local progression-free survival at 3 years was 84.3% in the SBRT group vs 67.3% in the RFA group, with...